Novavax Inc (NVAX)
$48.00
3.89 (7.50%)
NVAX Stock Quote Delayed 30 Minutes
Avoid Novavax Stock as Its Hopes Dwindle
The FDA approval is the only hope for Novavax. If you own it, hold NVAX stock until the approval but do not take a new position right now.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
3.58B
PE Ratio
-2.70
EPS
-17.81
Volume (Avg. Vol.)
3.51M
Day's Range
$47.89 - $53.50
52-Week Range
$41.33 - $277.80
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Why Is Novavax Stock Rising This Week?
The quarterly results and FDA approval for EUA could push NVAX stock higher in the coming weeks, so take your position now.
The Window of Opportunity Has Closed for Novavax
A series of missteps left Novavax far behind in the vaccine race. Continued delays and roadblocks continue to hurt NVAX stock.
Dear Novavax (NVAX) Stock Fans, Mark Your Calendars for June 7
NVAX stock is in the green after the FDA announced it would meet on June 7 to discuss the company's emergency use authorization request.
Novavax Stock Is Now Speculative, But it Still Has a Shot
NVAX stock has become speculative, but it still has multiple ways to win. The company needs to step up its marketing game.
Novavax Could Get Analyst Downgrades Leading Up to Earnings
Novavax recently got Nuvaxovid approved for use in Japan for both primary and booster shots. It’s done nothing for NVAX stock.
Novavax Stock Could Give Back More of Its Pandemic-Era Gains
While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium.
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.
Is Novavax a Buy After Its Vaccine Approval in Switzerland?
Novavax is late to the Covid-19 vaccine race and is up against some stiff competition. NVAX stock is in a tough spot.
What Volatility in Novavax Means for Investors
Novavax continues to await FDA news about its Covid-19 vaccine, but that's not everything that drives the price of NVAX stock.
The Longer the Wait, The Smaller the Opportunity for Novavax
The delay in FDA approval is making the opportunity smaller for Novavax, but the opportunity still remains. NVAX stock is a hold.
Novavax: The Party’s Over
Novavax made its vaccine in the traditional way and with an adjuvant to let it cover more people. But people still seem to prefer mRNA vaccines.
Will Novavax Stock Continue to Trend Lower?
NVAX stock is likely to remain depressed as the market for covid-19 vaccine shrinks. Combination vaccines can be a positive catalyst.
Novavax Stock Up on Swiss Approval of Nuvaxovid
Novavax’s Covid-19 vaccine Nuvaxovid just got approved for in Switzerland. NVAX stock is up on news. It couldn’t have come at a better time.
Novavax Stock Is Slumping: Why Buy the Dip?
Novavax lost nearly one-fifth of its value in the last week and risks further selling pressure, despite offering an mRNA alternative.
Novavax Stock Is Tanking Despite New Covid-19 Vaccine Authorization
NVAX stock isn't a darling on Wall Street right now, but a rally could be just around the corner as Novavax pursues its global ambitions.
Vaccine Makers Down on FDA Meeting, Novavax Most at Risk
The major covid-19 vaccine makers are all down, anticipating bad-for-business news from the FDA. However, NVAX stock has the most to lose.
Dear Biotech Investors: Novavax’s Comparable Vaccine Matters
Researchers compared Novavax’s vaccine to three others on the market, offering a thorough glimpse of protection from boosters.
Is NVAX Stock a Buy at 52-Week Low? Skip the Novavax Portfolio Injection
NVAX stock could slide even further as research & development requirements stack up against its balance sheet's capacity.
Novavax Just Hit a New Yearly Low, Here’s How To Buy It Even Lower
NVAX stock is still falling. Get paid for your patience to be a buyer at lower levels by selling expensive puts.
